General contact

Head Office
Novartis International AG
CH-4002 Basel

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

SEGA Tumors

Votubia® (everolimus) tablets

Votubia® (everolimus) tablets* is the first medical treatment approved in the European Union (EU) for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention and who are not likely to require surgery. The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated. Votubia is also offered in a dispersible formulation to better accommodate TSC patients with SEGA associated with TSC, including children who are unable to swallow tablets.

Votubia targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism.

For more information on other areas of research, please visit EVEROLIMUS in the research section.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative. Everolimus is not approved for this indication in all countries.

*Known as Votubia® (everolimus) tablets for this patient population in the EU and Switzerland. Approved in the US for this patient population under the trade name Afinitor® (everolimus) tablets.